Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

625.20
+6.251.01%
Volume:469.14K
Turnover:293.49M
Market Cap:66.10B
PE:15.23
High:633.89
Open:628.07
Low:621.11
Close:618.95
52wk High:821.11
52wk Low:476.49
Shares:105.72M
Float Shares:103.30M
Volume Ratio:0.59
T/O Rate:0.45%
Dividend:3.59
Dividend Rate:0.57%
EPS(TTM):41.06
EPS(LYR):41.48
ROE:14.55%
ROA:6.13%
PB:2.10
PE(LYR):15.07

Loading ...

Regeneron Treatment for Ebola Recommended for Priority Evaluation by WHO

Dow Jones
·
May 29

Regeneron Ebola antibody recommended by WHO for investigational use

TIPRANKS
·
May 29

Regeneron Pharmaceuticals Inc: Maftivimab Shown Broad Activity in Vitro Against Multiple Ebola Species, Including Bundibugyo

THOMSON REUTERS
·
May 29

Regeneron Pharmaceuticals Inc - Supply of Inmazeb Is Already on Ground in Drc

THOMSON REUTERS
·
May 29

Regeneron Pharmaceuticals - Preparing Maftivimab Supply for Clinical Trials; Inmazeb Available in Drc

THOMSON REUTERS
·
May 29

Regeneron Pharmaceuticals Inc: Maftivimab Has Been Recommended to Be Studied as a Monotherapy in Current Outbreak

THOMSON REUTERS
·
May 29

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

THOMSON REUTERS
·
May 29

WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak

Reuters
·
May 29

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
May 28

A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Trial Wins And New Research Partnership

Simply Wall St.
·
May 26

US Biotech Regeneron to Launch Global Capability Centre in India's Hyderabad - Statement

THOMSON REUTERS
·
May 26

Why Regeneron (REGN) Is Down 8.5% After Melanoma Trial Miss and New Legal Scrutiny - And What's Next

Simply Wall St.
·
May 24

Regeneron, Circle, Burlington, Ross, Pembina Trending With Analysts

TIPRANKS
·
May 23

FACTBOX-Bundibugyo Ebola vaccines and treatments in development

Reuters
·
May 23

Regeneron Says Otarmeni Application Accepted Under EU Accelerated Assessment

MT Newswires Live
·
May 22

EMA accepts Regeneron Otarmeni gene therapy filing for OTOF-related hearing loss review

Reuters
·
May 22

BRIEF-Otarmeni Receives EMA Filing Acceptance For Genetic Hearing Loss

Reuters
·
May 22

Otarmeni™ (Lunsotogene Parvec) Receives Ema Filing Acceptance for Genetic Hearing Loss

THOMSON REUTERS
·
May 22

Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)

TIPRANKS
·
May 22

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
May 21